The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cue Biopharma Inc shares valued at $30,900 were purchased by PASSERI DANIEL R on Dec 16 ’24. At $1.03 per share, PASSERI DANIEL R acquired 30,000 shares. The insider’s holdings grew to 164,578 shares worth approximately $0.24 million following the completion of this transaction.
As published in their initiating research note from Jefferies on March 13, 2024, Cue Biopharma Inc [CUE] has been a Buy and the price target has been revised to $6. As of November 21, 2022, Piper Sandler has initiated its “an Overweight” rating for CUE. Earlier on January 13, 2022, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for CUE stock.
Analyzing CUE Stock Performance
During the last five days, there has been a surge of approximately 33.03%. Over the course of the year, Cue Biopharma Inc shares have jumped approximately 33.03%. Shares of the company reached a 52-week high of $1.7500 on 01/06/25 and a 52-week low of $1.0200 on 01/02/25. A 50-day SMA is recorded $1.2802, while a 200-day SMA reached $1.2244. Nevertheless, trading volume fell to 0.17 million shares from 0.24 million shares the previous day.
Support And Resistance Levels for Cue Biopharma Inc (CUE)
According to the 24-hour chart, there is a support level at 1.3733, which, if violated, would cause prices to drop to 1.2967. In the upper region, resistance lies at 1.5633. The next price resistance is at 1.6767. RSI (Relative Strength Index) is 59.34 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.4100, which suggests the price will decrease in the coming days. Percent R is at 37.50%, indicating low price movement. Stochastics %K at selling indicates that the stock is to be held.
